Prescription medicine

Brolucizumab Brand names: Beovu

Brolucizumab (Beovu) is a prescription medicine. No generic is listed in FDA's NDC Directory.

No generic listed

Check it at the source: the brolucizumab FDA label on DailyMed (effective November 3, 2025); every brolucizumab label on DailyMed.

Highlights of the record

FDA label of November 3, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage
BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) 1.1 Neovascular (Wet) Age-related Macular Degeneration (AMD) 1.2 Diabetic Macular Edema (DME)

Forms and strengths

6 mg/.05ml

Injection (solution).

On the market

Generic approvals: No generic approved
Labelers listed (NDC): 1 of which 0 under generic applications, 1 under brand applications, repackagers included

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded
FAERS reports: 3,622 through July 30, 2026

What is brolucizumab used for?

From the label: indications and usage
BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) 1.1 Neovascular (Wet) Age-related Macular Degeneration (AMD) 1.2 Diabetic Macular Edema (DME)

Source: FDA drug label (BEOVU), Novartis Pharmaceuticals Corporation, effective November 3, 2025 (SPL set 5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d), via openFDA; the full label on DailyMed

Is there a generic for brolucizumab (Beovu)?

No generic brolucizumab is approved (Drugs@FDA, October 8, 2026).

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do FAERS reports show for brolucizumab?

The FDA Adverse Event Reporting System holds 3,622 reports that list brolucizumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 245 are coded as a death and 280 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2020 (1,252, against a median of 185 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.

Reports received each year

The most reported reactions

Visual Impairment (named in the label)569
Vitreous Floaters (named in the label)558
Vision Blurred (named in the label)533
Eye Inflammation (named in the label)447
Visual Acuity Reduced (named in the label)434
Retinal Vasculitis (named in the label)383
Uveitis (named in the label)361
Vitritis (named in the label)356

Side effects: the label's list and every FAERS reaction

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What next?

Brolucizumab side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other